Ventyx Biosciences, Inc.

NasdaqGS:VTYX Stock Report

Market Cap: US$346.1m

Ventyx Biosciences Management

Management criteria checks 2/4

Ventyx Biosciences' CEO is Raju Mohan, appointed in Nov 2018, has a tenure of 5.5 years. total yearly compensation is $9.41M, comprised of 6.3% salary and 93.7% bonuses, including company stock and options. directly owns 2.24% of the company’s shares, worth $7.75M. The average tenure of the management team and the board of directors is 4.2 years and 3 years respectively.

Key information

Raju Mohan

Chief executive officer

US$9.4m

Total compensation

CEO salary percentage6.3%
CEO tenure5.5yrs
CEO ownership2.2%
Management average tenure4.2yrs
Board average tenure3yrs

Recent management updates

Recent updates

Ventyx Pivots To Obesity Amid Transformation

Mar 12

Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation

Feb 15
Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation

Ventyx: Too Risky Right Now After Some Poor Data

Jan 18

Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth

Sep 21
Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth

Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans

Jun 07
Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Feb 20
We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Ventyx Biosciences: Not Chasing This Rally

Sep 18

We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Aug 19
We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06

Aug 15

Ventyx Biosciences autoimmune/autoinflammatory candidate meets phase 1 goals

Jun 29

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

May 06
We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Jan 21
We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Raju Mohan's remuneration changed compared to Ventyx Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$9mUS$596k

-US$193m

Sep 30 2023n/an/a

-US$181m

Jun 30 2023n/an/a

-US$158m

Mar 31 2023n/an/a

-US$125m

Dec 31 2022US$4mUS$567k

-US$108m

Sep 30 2022n/an/a

-US$91m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$15mUS$423k

-US$85m

Sep 30 2021n/an/a

-US$84m

Jun 30 2021n/an/a

-US$79m

Mar 31 2021n/an/a

-US$65m

Dec 31 2020US$68kUS$37k

-US$28m

Compensation vs Market: Raju's total compensation ($USD9.41M) is above average for companies of similar size in the US market ($USD2.40M).

Compensation vs Earnings: Raju's compensation has increased whilst the company is unprofitable.


CEO

Raju Mohan (65 yo)

5.5yrs

Tenure

US$9,411,949

Compensation

Dr. Raju S. Mohan, Ph.D. founded Ventyx Biosciences, Inc. in November 2018 and serves as its Chief Executive Officer and Director since then and serves as its President since November 22, 2023. Dr. Mohan h...


Leadership Team

NamePositionTenureCompensationOwnership
Sheila Gujrathi
Executive Chairperson3yrsUS$486.29k0%
$ 0
Raju Mohan
Founder5.5yrsUS$9.41m2.24%
$ 7.7m
John Nuss
Chief Scientific Officer5.3yrsUS$3.89m0.38%
$ 1.3m
Martin Auster
Chief Financial Officer3yrsno data0%
$ 0

4.2yrs

Average Tenure

58.5yo

Average Age

Experienced Management: VTYX's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sheila Gujrathi
Executive Chairperson3yrsUS$486.29k0%
$ 0
Raju Mohan
Founder5.5yrsUS$9.41m2.24%
$ 7.7m
William Sandborn
Chairman of Clinical Advisory Boardno dataUS$4.16m0.10%
$ 356.4k
Allison Hulme
Independent Director1.3yrsUS$834.42k0%
$ 0
Somasundaram Subramaniam
Independent Director5.5yrsUS$417.35k0%
$ 0
Alexa Kimball
Member of Clinical & Scientific Advisory Boardno datano datano data
James Krueger
Member of Clinical & Scientific Advisory Boardno datano datano data
Bruce Sands
Member of Clinical & Scientific Advisory Boardno datano datano data
Emma Guttman-Yassky
Member of Clinical & Scientific Advisory Boardno datano datano data
William White
Independent Director3yrsUS$416.29k0%
$ 0
Luisa Salter-Cid
Member of Advisory Boardno datano datano data
Onaiza Cadoret-Manier
Independent Director1.3yrsUS$837.34k0%
$ 0

3.0yrs

Average Tenure

59yo

Average Age

Experienced Board: VTYX's board of directors are considered experienced (3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.